Correlation Between Spyre Therapeutics and Summit Midstream

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and Summit Midstream at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and Summit Midstream into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and Summit Midstream, you can compare the effects of market volatilities on Spyre Therapeutics and Summit Midstream and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of Summit Midstream. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and Summit Midstream.

Diversification Opportunities for Spyre Therapeutics and Summit Midstream

-0.39

Correlation Coefficient

Spyre Therapeutics  Summit Midstream

Very good diversification

The 3 months correlation between Spyre and Summit is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and Summit Midstream in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Summit Midstream and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with Summit Midstream. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Summit Midstream has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and Summit Midstream go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and Summit Midstream

Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the Summit Midstream. In addition to that, Spyre Therapeutics is 2.45 times more volatile than Summit Midstream. It trades about -0.03 of its total potential returns per unit of risk. Summit Midstream is currently generating about 0.09 per unit of volatility. If you would invest  3,503  in Summit Midstream on October 7, 2024 and sell it today you would earn a total of  297.00  from holding Summit Midstream or generate 8.48% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Spyre Therapeutics  vs.  Summit Midstream

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Summit Midstream

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Summit Midstream are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Summit Midstream may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Spyre Therapeutics and Summit Midstream

The main advantage of trading using opposite Spyre Therapeutics and Summit Midstream positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, Summit Midstream can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Summit Midstream will offset losses from the drop in Summit Midstream's long position.

The idea behind Spyre Therapeutics and Summit Midstream pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.